Becton Dickinson Q3 revenue beats on product launches

Overview

• US medical technology firm's fiscal Q3 revenue rose 5.4%, beating analyst expectations

• Adjusted EPS for fiscal Q3 increased 4.9%, beating analyst expectations

• Company raised midpoint of full-year adjusted EPS guidance, expects revenue growth toward high end

Outlook

• Company expects full-year revenue growth toward the high end of its range

• Becton Dickinson raises midpoint of full-year adjusted diluted EPS guidance to $12.62-$12.72

• Company maintains full-year GAAP revenue growth outlook at low single-digit plus

Result Drivers

• SEGMENT GROWTH - Co cited strong momentum across Medical Essentials, Connected Care, BioPharma Systems and Interventional segments following spin-off

• PRODUCT LAUNCHES AND COLLABORATIONS - Recent launches and partnerships, including Vizient contract for CentroVena One and semaglutide launch with EMS, contributed to segment performance

• DISCIPLINED EXECUTION - Management attributed margin expansion and adjusted EPS growth to disciplined execution and strategic capital allocation

Company press release: ID:nPn78LCp3a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies distribution peer group is "buy"

• Wall Street's median 12-month price target for Becton Dickinson and Co is $182.00, about 6.6% above its August 5 closing price of $170.66

• The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads

• Aug 5 - Steris Q1 adjusted EPS beats estimates, revenue up 7%

• Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand

• Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)